Akums Drugs & Pharmaceuticals Ltd. has announced the launch of Lasmiditan dispersible tablets, approved by the DCGI, for the acute treatment of migraine in adults.

Lasmiditan belongs to the ‘ditans’ class of anti-migraine drugs and acts as a selective serotonin 5-HT1F receptor agonist. It is indicated for the treatment of migraine with or without aura and is not intended for preventive therapy.

The dispersible formulation is designed for administration during migraine episodes and can be mixed in a small quantity of water, enabling intake in patients experiencing nausea, vomiting, gastric stasis, and difficulty swallowing.

The formulation incorporates a dual disintegration mechanism of swelling and effervescence for rapid dispersion. It also includes taste-masking technology to address the bitter taste of Lasmiditan.

Lasmiditan has a higher binding affinity for the 5-HT1F receptor compared to 5-HT1B/1D receptors, enabling targeted action on migraine pathways.

The launch introduces a dispersible dosage form of Lasmiditan for the acute treatment of migraine.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!